摘要
目的:观察人参皂甙Rg3联合三氧化二砷对裸鼠肝癌移植瘤模型的作用。方法:实验于2005-04/12在广州医学院动物实验室进行。取24只雄性裸鼠(BALB/C-nu/nu),将体外培养人肝癌Bel-7402细胞株种植于左前上肢腋窝皮下,然后单纯随机分为4组(n=6):①人参皂甙Rg3组:自接种肝癌细胞株第3天起,灌胃给予10mg/kg人参皂甙Rg3,隔日1次,灌胃20次。②三氧化二砷组:自接种肝癌细胞株第3天起,腹腔内注射三氧化二砷40μg/d,1次/d,连续28d。③联合用药组:同时用人参皂甙Rg3灌胃和三氧化二砷腹腔注射,用药量和时间同上2组。④对照组:等量生理盐水灌胃,方法同人参皂甙Rg3组。停药1周后分别观察裸鼠的生存质量(包括精神状态、活动状况、对刺激的反应、体质量下降幅度、食欲和尿、便6项指标),测定瘤质量,计算肿瘤抑制率,计数肿瘤内微血管密度。结果:①治疗方案结束时,联合用药组6只裸鼠均存活,人参皂甙Rg3组和三氧化二砷组有5只存活,对照组只有4只存活。人参皂甙Rg3组和联合用药组荷瘤裸鼠生存质量较高。②人参皂甙Rg3组、三氧化二砷组和联合用药组平均瘤质量明显轻于对照组[(0.83±0.22),(0.68±0.16),(0.56±0.11),(1.52±0.60)g,P<0.05],但前3组之间差异不显著(P>0.05)。③人参皂甙Rg3组、三氧化二砷组和联合用药组肿瘤抑制率分别为45.1%,55.3%,63.1%,3组比较差异不显著。④人参皂甙Rg3组、三氧化二砷组和联合用药组肿瘤内微血管密度明显低于对照组[(12.71±2.75),(18.00±2.24),(10.00±2.92),(27.00±2.94)个/200倍视野,P<0.05],人参皂甙Rg3组和联合用药组微血管密度值低于三氧化二砷组(P<0.05),但2组间比较差异不显著(P>0.05)。结论:人参皂甙Rg3能明显抑制肿瘤新生血管形成,与三氧化二砷联合应用具有协同作用,能明显抑制裸鼠肝癌移植瘤的生长,改善荷瘤裸鼠生存质量。
AIM： To study the effect of integrated method of arsenic trioxide and ginsenoside Rg3 on transplanted hepatic carcinoma in nude mice.
METHODS： The experiment was conducted in the Animal Laboratory of Guangzhou Medical College from April 2005 to December 2005. Twentyfour male nude rats （BALG/C-nu/nu） were selected and randomly divided into 4 groups （n=6） after being transplanted with in vitro cultured Bel- 7402 cell strain at the subcutaneous of armpit in left anterior-superior limbs.①Ginsenoside Rg3 group： Rats received gastric perfusion of ginsenoside Rg3 （10 mg/kg） on the 3^nd day after inoculation of hepatoma carcinoma cell （HCC） strain once every other day for totally 20 times.②Arsenic trioxide group： Rats were given intraperitoneal injection of arsenic trioxide once a day and 40μg each time for totally 28 days.③Integrated treatment group： Rats received gastric perfusion of Ginsenoside Rg3 and arsennic trioxide at the dose and time the same as above-mentloned two groups.④Control group： Rats received intragastric administration of normal saline with the same method of Ginsenoside Rg3 group. One week after discontinuation, the quality of life （including mental state, activity, response to stimulus, decrease of body mass, appetite, urine and stool） were observed in nude rats, and the size of tumor, the tumor control rate as well as the microvessel density （MVD） were calculated and measured respectively.
RESULTS： ①After the treatment, 6 rats in the integrated treatment group, 5 rats in Ginsenoside Rg3 group, 5 rats in the arsenic trioxide group and 4 rats in the control group survived. The life quality of nude rats in Ginsenoside Rg3 group and integrated treatraent group were obviously better.②The average tumor weight of rats in the Ginsenoside Rg3 group, arsenic trioxide group and integrated treatment group were obviously lighter than the control group [（0.83±0.22）, （0.68±0.16）, （0.56±0.11 ）, （1.52±0.60） g,P 〈 0.05], while the differences among the former 3 groups were not significant （P 〈 0.05）.③The tumor inhibition ratio in Ginsenoside Rg3 group, arsenic trioxide group and integrated treatment group were 45.1%, 55.3% and 63.1% respectively, and the differences among 3 groups were not marked.④The MVD value of Ginsenoside Rg3 group, arsenic trioxide group and integrated treatment group were significantly lower than the control group [（12.71±2.75）, （18.00 ±2.24）, （10.00±2.92）, （27.00±94）/200 times of vision-field ,P 〈 0.05], and that of Ginsenoside Rg3 group and integrated treatment group were obviously lower than the arsenic trioxide group （P 〈 0.05）, but there was no significant difference between two groups （P 〉 0.05）.
CONCLUSION： Ginsenoside Rg3 can obviously inhibit tumor neovascularity. Integrated with arsenic trioxide, Ginsenoside Rg3 can remarkably inhibit the growth of transplanted hepatic carcinoma as well as ameliorate the life quality in nude mice.
出处
《中国临床康复》
CSCD
北大核心
2006年第31期120-122,共3页
Chinese Journal of Clinical Rehabilitation
基金
广州市卫生局基金资助项目~~
